Q-omics provides the consensus-scored TMEM41B profile across patient tissues and cancer cell-line models. TMEM41B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM41B is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, TMEM41B RNA expression shows 20,510 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and BLCA as cancer lineages where TMEM41B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM41B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM41B survival associations across molecular data types. TMEM41B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM41B RNA expression–survival associations across cancer types. High TMEM41B expression shows unfavorable associations in ACC, KICH, LIHC, HNSC and ESCA, but favorable associations in SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM41B RNA expression.
This table summarizes TMEM41B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM41B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM41B shows lower tumor expression in LUAD and higher tumor expression in BLCA, STAD, HNSC, LIHC and BRCA. The BLCA box plot shows higher TMEM41B RNA expression in tumor versus normal tissue (log2 FC = +1.239, t-test p < 0.001).
This table shows molecular features associated with TMEM41B in patient tissues and cancer cell lines. In patient samples, TMEM41B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM41B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
